Clozapine reduced cannabis craving and brain cue reactivity more than risperidone in patients with schizophrenia
A randomized fMRI study of 38 schizophrenia patients found that clozapine reduced both subjective cannabis craving and amygdala activation to cannabis images significantly more than risperidone after 4 weeks of treatment.
Quick Facts
What This Study Found
Thirty-eight patients with schizophrenia (30 with cannabis use disorder, 8 without) and 20 healthy controls were included. Patients were randomized to clozapine or risperidone.
At baseline, patients with comorbid cannabis use disorder showed higher subjective craving and greater brain activation to cannabis-related images compared to those without CUD and healthy controls, across most regions of interest.
After 4 weeks of treatment, clozapine-treated patients reported significantly greater reduction in craving (F=6.0, p=0.04) and showed a larger decrease in amygdala activation during cannabis-related images compared to risperidone-treated patients (T=3.94, p=0.006).
Subjective craving correlated significantly with thalamus and insula activation during cannabis cue exposure.
The findings provide neurobiological evidence for clozapine's superiority in this dual-diagnosis population, likely through differential effects on dopamine signaling.
Key Numbers
38 patients, 20 controls. Craving reduction: clozapine > risperidone (F=6.0, p=0.04). Amygdala activation decrease: clozapine > risperidone (T=3.94, pFWE=0.006). Craving correlated with thalamus and insula activation.
How They Did This
Randomized fMRI study. 38 schizophrenia patients (30 with CUD, 8 without) and 20 healthy controls. Randomized to clozapine or risperidone. Brain response to cannabis-related, positive, and neutral images at baseline and 4 weeks. ROIs: amygdala, ventral striatum, insula, thalamus, orbitofrontal cortex, anterior cingulate.
Why This Research Matters
Cannabis use disorder in schizophrenia is extremely common and worsens outcomes. Clozapine is often recommended for this population but evidence for why has been limited. This study provides both subjective and neurobiological evidence that clozapine reduces cannabis craving more effectively than risperidone.
The Bigger Picture
Dual-diagnosis patients (schizophrenia plus cannabis use disorder) represent one of the most challenging clinical populations. Evidence-based guidance on antipsychotic choice for this group is limited, making this small RCT an important contribution.
What This Study Doesn't Tell Us
Small sample size (38 patients). Short treatment duration (4 weeks). Unequal group sizes for CUD status. Open-label medication assignment. Cannot determine whether craving reduction translates to actual cannabis use reduction long-term.
Questions This Raises
- ?Does clozapine's craving reduction translate to sustained cannabis abstinence?
- ?Is the amygdala the key brain region mediating clozapine's advantage?
- ?Would other atypical antipsychotics show similar effects?
Trust & Context
- Key Stat:
- Clozapine reduced amygdala cannabis cue reactivity significantly more than risperidone (p=0.006)
- Evidence Grade:
- Moderate. Randomized design with neuroimaging outcomes, but small sample and short duration limit conclusions.
- Study Age:
- Published in 2018. Clozapine remains a recommended option for schizophrenia with comorbid substance use disorders.
- Original Title:
- Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.
- Published In:
- Schizophrenia research, 194, 32-38 (2018)
- Authors:
- Machielsen, Marise W J, Veltman, Dick J(3), van den Brink, Wim(10), de Haan, Lieuwe
- Database ID:
- RTHC-01740
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What is cue reactivity?
Cue reactivity refers to the brain's response to substance-related stimuli (like images of cannabis). Higher cue reactivity indicates stronger automatic responses that can trigger craving and relapse. Reducing cue reactivity with medication may help patients resist urges to use.
Why is clozapine not used more often?
Clozapine requires regular blood monitoring due to a rare but serious risk of agranulocytosis (dangerous drop in white blood cells). This monitoring burden means it is typically reserved for treatment-resistant cases, despite evidence of superiority in certain populations.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01740APA
Machielsen, Marise W J; Veltman, Dick J; van den Brink, Wim; de Haan, Lieuwe. (2018). Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.. Schizophrenia research, 194, 32-38. https://doi.org/10.1016/j.schres.2017.03.030
MLA
Machielsen, Marise W J, et al. "Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.." Schizophrenia research, 2018. https://doi.org/10.1016/j.schres.2017.03.030
RethinkTHC
RethinkTHC Research Database. "Comparing the effect of clozapine and risperidone on cue rea..." RTHC-01740. Retrieved from https://rethinkthc.com/research/machielsen-2018-comparing-the-effect-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.